Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for iTeos Therapeutics, Inc. (ITOS : NSDQ)
 
 • Company Description   
iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery and development of immuno-oncology therapeutics. iTeos Therapeutics Inc. is based in Cambridge, United States.

Number of Employees: 94

 
 • Price / Volume Information   
Yesterday's Closing Price: $16.95 Daily Weekly Monthly
20 Day Moving Average: 571,056 shares
Shares Outstanding: 35.54 (millions)
Market Capitalization: $602.41 (millions)
Beta: 1.94
52 Week High: $52.43
52 Week Low: $16.36
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -43.50% -36.36%
12 Week -52.67% -47.96%
Year To Date -63.60% -55.52%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
321 ARSENAL STREET BLDG 312 FLOOR 3 SUITE 301
-
WATERTOWN,MA 02472
USA
ph: 339-217-0161
fax: -
ir@iteostherapeutics.com http://www.iteostherapeutics.com
 
 • General Corporate Information   
Officers
Michel Detheux - Chief Executive Officer and Director
David L. Hallal - Chairman of the Board of Directors
Matthew Gall - Chief Financial Officer
Aaron Davis - Director
Derek DiRocco - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 46565G104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 35.54
Most Recent Split Date: (:1)
Beta: 1.94
Market Capitalization: $602.41 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $1.20 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $4.38 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 3.87
Trailing 12 Months: 2.17
PEG Ratio: -
Price Ratios
Price/Book: 0.96
Price/Cash Flow: 2.78
Price / Sales: -
EPS Growth
vs. Year Ago Period: 566.67%
vs. Previous Quarter: -62.70%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -36.58%
ROE
03/31/22 - 64.68
12/31/21 - 56.20
09/30/21 - 4.55
ROA
03/31/22 - 40.01
12/31/21 - 34.90
09/30/21 - 3.08
Current Ratio
03/31/22 - 4.82
12/31/21 - 2.88
09/30/21 - 1.69
Quick Ratio
03/31/22 - 4.82
12/31/21 - 2.88
09/30/21 - 1.69
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - 78.33
12/31/21 - 74.39
09/30/21 - 16.80
Book Value
03/31/22 - 17.62
12/31/21 - 15.67
09/30/21 - 10.57
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©